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Abstract
This article offers a counter narrative to the current ethnographic studies on treatment with
buprenorphine, in which notions of promised and experienced normality dominate. In some
countries, introduction of buprenorphine led to a perceived “normalisation” of opioid substitution
treatment, and this new modality was well received. However, in Norway the response has been
almost the opposite: patients have reacted with feelings of disenfranchisement, failure, and mis-
trust. Based on ethnographic fieldwork in Norway, this article offers comparative insight into local
experiences and subjectivities in the context of the globalisation of buprenorphine. By outlining the
ethnographic description of the pharmaceutical atmosphere of forced transfers to buprenorphine-
naloxone, I show that the social history of the medication is as significant as its pharmacological
qualities for various treatment effects. An analysis of the reactions to this treatment modality
highlights the reciprocal shaping of lived experiences and institutional forces surrounding phar-
maceutical use in general and opioids in particular.
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In her article, “To be free and normal: Addic-
tion, governance, and the therapeutics of
buprenorphine”, Harris (2015) discussed how
buprenorphine1 treatment offers patients
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addicted to heroin and their providers “a greater
sense of autonomy and flexibility in how they
receive and deliver treatment” (p. 512). She
also suggested that it “simultaneously perpetu-
ates and shapes a desire to be ‘free’ and ‘nor-
mal’” (2015, p. 512). The notions of promised
and experienced normality dominate the few
available ethnographic studies on perceptions
and experiences with buprenorphine. The
majority of this research has been conducted
in the United States, where this new modality
was well received and buprenorphine led to
perceived normalisation of treatment (e.g., Harris,
2015; Netherland, 2011). In Norway, however,
the atmosphere around buprenorphine-based
medications has been almost the exact
opposite.
During my fieldwork, I observed that the
buprenorphine-naloxone product (Suboxone®)
in particular elicited negative emotions and
hostile reactions among patients. Feelings of
disenfranchisement and social and clinical
injustice dominated their narratives. Patients
described Suboxone® as the worst alternative
among opioid substitution treatment (OST)
medications and as having many side effects,
the most disturbing one being dizziness and
debilitating anxieties (see also Muller, Bjørnes-
tad, & Clausen, 2018). Available ethnographic
studies on buprenorphine (e.g., Harris, 2015;
Lovell, 2006; Meyers, 2013) do not report the
negative experiences so prevalent in Norwegian
treatment discourse, nor do they distinguish
between pure buprenorphine and
buprenorphine-naloxone. Therefore, in this
study, I was driven to ask these empirical ques-
tions: What may have conditioned buprenor-
phine products, particularly Suboxone®, to be
such an unpopular medication among patients
in Norway? What has shaped its reception, and
how has the clinical community interpreted
patients’ reactions?
Based on archival studies and ethnographic
fieldwork conducted in Norway, this article
offers an insight into local experiences and sub-
jectivities in the context of the globalisation of
buprenorphine. A historical outline of the OST
pharmaceutical atmosphere around the intro-
duction of Suboxone® in particular and an anal-
ysis of the reception and current resistance to
this treatment modality highlight the reciprocal
shaping of lived experiences and the institu-
tional forces surrounding pharmaceutical use
in general and opioids in particular.
Theoretical framework
Analyses of lived experiences and subjectivities
related to the consumption of pharmaceuticals
question the pharmacotopic view of pharma-
ceutical treatment (e.g., Jenkins, 2015; Ninne-
mann, 2012; Sanabria, 2014). I define
pharmacotopia as an idealised and overly opti-
mistic imaginary of pharmaceuticals’ universal
efficacy. The expectation is that patients will
respond to particular medications in a similar
way, a promised narrative promoted by global
marketing forces, supported by the pharmaco-
logical research community, and eagerly repro-
duced by local clinicians in encounters with
patients. Driving these imaginaries is the under-
lying assumption that biological bodies react
universally in all settings, but also that clinical
contexts are devoid of local singularities. How-
ever, researchers have documented individual
responses to pharmaceuticals and have pointed
out that cultural and social contexts shape how
patients taking pharmaceuticals perceive and
report effects and side effects of medications
(Etkin, 1992; Ninnemann, 2012; van der Geest
& Hardon, 2006; Zinberg, 1984). Previous stud-
ies on OST have also demonstrated that sub-
stances do not have a priori qualities and that
they change according to their use, location,
socio-political contexts, and related discourses
(Gomart, 2002; Keane, 2013). Yet clinical prac-
titioners, as well as scholars investigating phar-
macological efficacy, often lean on narrow,
biologically reductionist definitions and there-
fore view drug effects as predominantly a prod-
uct of pharmaceutical action. In line with an
increasing number of scholars, this article
emphasises a deeper understanding, resting on
exploration of how the cultural, socio-political,
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institutional, and biological processes, sepa-
rately and in combination, mediate treatment
responses (e.g., Lawson, 2008; Malhotra,
2001; Sanabria, 2014; Schlosser & Ninnemann,
2012).
As ideas, values, knowledge, technologies,
and pharmaceuticals travel, so does buprenor-
phine and its promised narrative. “When ideas
like ‘metabolic lesion’ and techniques such as
[Methadone maintenance treatment] become
truly cosmopolitan, however, they settle into
certain institutional landscapes at particular his-
torical moments,” Saris (2008, p. 267) pointed
out. My interlocutors’ engagements with
buprenorphine evolved in a particular socio-
pharmaceutical landscape with its local
histories, political struggles, moral constraints,
and bodily sensations that constitute what I call
pharmaceutical atmosphere. Here, atmosphere
refers to both an empirical reality and an
analytical category, which I apply to capture
the prevailing tone and mood relating to
buprenorphine in Norway. Bo¨hme (1993)
wrote:
Atmospheres are indeterminate above all as
regards their ontological status. We are not sure
whether we should attribute them to the objects or
environments from which they proceed or to the
subjects who experience them. We are also
unsure where they are. They seem to fill the space
with a certain tone of feeling like a haze. (Bo¨hme,
1993, p. 114)
Thus, if we follow Anderson’s (2009) under-
standing of atmosphere as “shared ground from
which subjective states and their attendant feel-
ings and emotions emerge” (p. 78), then the
pharmaceutical atmosphere is that shared
ground related to pharmaceutical use. The phar-
maceutical atmosphere that I explore empiri-
cally appears as a hazy composite of
individual and shared emotions, clinical prac-
tices, political tensions, and legal and scientific
narratives that are manifested in human bodies.
As a potential that emerges effectively at the
conceptual and sensory levels, pharmaceutical
atmospheres are an important part of pharma-
ceutical efficacy. While affecting relations
between people and drugs, atmospheres are also
political. They inform the ways in which both
patients and treatment providers describe or
think about themselves and others, and the ways
in which they are described by others in relation
to pharmaceutical use.
Context: Opioid substitution
treatment in Norway
In opioid substitution treatment (OST), patients
with opiate addiction receive a long-lasting
opioid substitute for – usually illegal – heroin
under controlled conditions. These substitutes,
such as methadone or buprenorphine, are said to
eliminate heroin withdrawal symptoms and
reduce cravings while blocking the effect of
injected heroin. Methadone treatment became
available first in the United States in the
1960s, after physician Vincent P. Dole and psy-
chiatrist Marie Nyswander developed this med-
ication for treatment of addiction, which they
defined as “a metabolic disease” (Dole & Nys-
wander, 1965, 1967). Gradually, substitution
medication – methadone, and later buprenor-
phine – emerged as the dominant treatment for
heroin addiction worldwide.
Treatment of opioid addiction with substitu-
tion medication has shown an increased patient
survival rate, along with a diminution in health
damage, criminal behaviour, and somatic dis-
eases, compared with psychosocial treatment
alone (Hedrich et al., 2012; Riksheim, Gossop,
& Clausen, 2014; Skeie et al., 2011).
However, in Norway throughout the 1970s
and 1980s, policy makers largely viewed med-
ication in treatment of substance addiction with
scepticism. The most prevalent arguments
against substitution medication were based on
optimism surrounding medication-free treat-
ment. Methadone was symptomatic of a
degrading attitude toward one’s fellow human
beings and a loss of faith in people suffering
from addiction and their ability to change. It
was as if methadone condemned people to
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lifelong addiction (Frantzsen, 2001; Skretting
& Rosenqvist, 2010). Opposition to pharmaceu-
tical treatment at that time may have been a
reflection of the medical profession’s relatively
minor role in the addiction field, which was
primarily dominated by social workers and, to
a lesser extent, psychologists. However, with
the Substance Treatment Reform in 2004,
responsibility for treatment of addiction moved
from social services to specialised healthcare.
Also, fearing an HIV epidemic in 1997, the
Norwegian Parliament, accepted a harm reduc-
tionist approach and allowed access to pharma-
ceutical treatment. Hence, methadone treatment
became available through a nationwide pro-
gramme, methadone assisted rehabilitation, in
1998. The treatment is mainly outpatient, with
medication supplied free of charge at a local
pharmacy or through the OST centre. Patients
pay deductibles for outpatient examination,
consultation in a hospital, and urine testing,
although treatment team meetings are free. Cur-
rent OST guidelines recommend three types of
substitution medication: methadone, high-dose
buprenorphine (Subutex® or Buprenorphine2),
and a buprenorphine-naloxone combination
(Suboxone®). Other medications, such as mor-
phine, can be used if the prescriber documents
reasons for diverging from the guidelines. Cur-
rently, there are four main recommendations
regarding the choice of medication:
1. Buprenorphine should be the first drug
of choice during substitution treatment.
2. Patient’s preference should be empha-
sised in the choice of medication.
3. Buprenorphine should be prescribed as
a combination product with naloxone
(Suboxone®).
4. Stable and drug-free patients should be
able to use the mono-product, Subutex®,
if there is no suspicion of diversion or
injection.3 (Helsedirektoratet, 2010, pp.
51–52)
The OST system aims for a rather high
degree of control. For both methadone and
buprenorphine products, medication must be
taken under daily supervision until evaluations
indicate the patient has stabilised and gained
sufficient control over his or her drug use. In
reality, this means the patient provides urine
samples free of illicit and non-prescribed drugs.
Once the patient stabilises, self-administration
of the medication at home may be granted to an
increasing extent. Medication lasting for up to a
week – or more, depending on pre-approved
travel plans – may be available in such cases.
The proportion of OST patients on metha-
done treatment has been steadily declining.
Currently, buprenorphine is mostly used as a
mono-preparation and less frequently as a com-
bined preparation. Interestingly, the variation
between counties is huge. Methadone treatment
is more prevalent at OST centres in the eastern
regions compared with those in western regions
and central Norway, where it is rare. According
to the Norwegian Centre for Addiction
Research (SERAF) at the University of Oslo,
this difference is difficult to explain in terms
of treatment indications or clinical issues (Waal
et al., 2017) and seems to illustrate local varia-
tions in interpretation and practice of national
guidelines. Most decisions made in the local
OST centres are dependent upon the attending
physician in charge of prescriptions, who is
influenced by personal preferences, local orga-
nisational structure, and culture (Bartoszko,
2018a; Gjersing, Waal, Røislien, Gossop, &
Clausen, 2011).
At the end of 2017, 7622 patients were in
OST. The average age of these patients was
44.9 years and approximately 70% were men
(Waal, Bussesund, Clausen, Lillevold, & Skeie,
2018).
Data and methods
The overall objective of my fieldwork was to
explore the experiences of OST patients within
the context of the 2004 Substance Treatment
Reform, which granted rights to persons diag-
nosed with dependence syndrome. Increas-
ingly, I focused particularly on patients’
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experiences with a change of treatment modal-
ities that appeared to be contentious. During a
year-long (2013–2014) ethnographic fieldwork
in several Norwegian municipalities, I closely
followed six patients who wished to switch or
keep their medication. OST patients are a het-
erogeneous group: those leading very stable,
mainstream lives; those actively engaged in
hustling in open drug scenes; and those in
between these two extremes. My interlocutors
belonged to all categories. They used different
combinations of medications depending on
their condition and geographical location. The
interlocutors were recruited through a snowbal-
ling method, beginning with my initial contact
with an OST patient who was recruited through
a personal network. Participation in the study
was based on an informed consent procedure
approved by the Norwegian Centre for
Research Data. The Regional Committees for
Medical and Health Research Ethics (REK)
evaluated the project and found no reason to
apply additional regulations specific to medical
and health research.
Participant observation was a key fieldwork
component. Among other things, I accompa-
nied the patients during OST consultations,
pre-hospitalisation meetings, and meetings with
their treatment teams, lawyers, or patient asso-
ciations. I also followed them through their
everyday OST activities, such as visits to phar-
macies, low-threshold health clinics, detoxifi-
cation units, and urine-collection sites. While
the most intensive relationships were developed
with these six patients, I also met their friends,
friends-of-friends, and other OST patients, who
shared their stories. Many of them were satis-
fied with their treatment.
Altogether, I collected around 40 treatment
stories from patients of different ages, treatment
experiences, and preferences. In addition, I par-
ticipated in relevant events such as patient gath-
erings, workshops, local professional addiction
conferences, seminars, and courses, which
yielded insight into the main narratives and
rationales in the field. I also conducted over
60 in-depth interviews with representatives of
patient organisations, addiction researchers,
OST physicians, OST consultants, social work-
ers, general practitioners, health bureaucrats,
patient ombudsman, and lawyers.
Ethnographic field notes included “close,
detailed reports of interaction” and “records of
actual words, phrases, or dialogue” (Emerson,
Fretz, & Shaw, 1995, pp. 14, 32). For the pur-
pose of this study, I coded notes, transcripts
from recorded interviews, documents (e.g.,
health records, OST guidelines, and white
papers), and archival media articles, analysing
them for key empirical themes related to bupre-
norphine. I further analysed these themes
against keywords from clinical guidelines (such
as “side effects”), from empirical and analytical
concepts found in previous ethnographic stud-
ies on buprenorphine (such as “normalisation”)
and from health sociology and anthropology
(such as “placebo”), in order to discover how
these corresponded to the ideas and experiences
of patients and clinicians in treatment practices
in Norway.
Buprenorphine and
buprenorphine-naloxonesettling in
Sociologist Esben Houborg (2012) used the
term “political pharmacology” in his work on
methadone and heroin in Danish drug policy.
He highlighted that the social construction of
drugs is a political affair, including questions
of how “different kinds of knowledge and dif-
ferent concerns are represented and negotiated
when drugs are constituted in particular ways”
(Houborg, 2012, p. 159). These clinico-
political constructions – together with individ-
ual and shared emotions, clinical practices,
political tensions, and legal and scientific nar-
ratives – shape pharmaceutical atmospheres.
Therefore, how OST medications were intro-
duced and marketed is significant for a better
understanding of the current Norwegian OST
atmosphere.
When the Norwegian Parliament decided to
allow pharmaceutical treatment for opioid
addiction, methadone was the first medication
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available. This moment in Norway’s pharma-
ceutical history, alongside global develop-
ments, shaped the present-day policy and
discourse regarding substitution medication,
including their clinical and public reception.
In an interview, Casper Monstad,4 a leading
researcher in addiction medicine and pharma-
cology in Norway, stated his understanding of
the relationship between clinically related phar-
maceutical innovations and the political
landscape:
When they [the politicians and clinicians]
started OST, even if I know perfectly the reason
for it, they have married one drug. The pro-
gramme was called methadone assisted rehabili-
tation [Metadonassistert rehabilitering] back
then. This made sense in many ways [ . . . ] The
decision-making process made it possible for the
programme, if implemented, to stay among pol-
iticians [laughs]. Obviously, they should take all
the important decisions. However, when they
decided upon the medication substance, it
became [politicised]. Later, when they started,
about 2000, 2001 I think, to explore the possibi-
lities of using another drug, buprenorphine or
what was named just Subutex®, the extent of
using another substance, too, was politicised.
[ . . . ] I say this because the decision regarding
treating our drug addicts, including the types of
drugs, even contexts, has moved from the clin-
ical to the political arena.
Exploring further the history of buprenor-
phine, I asked Andreas Bore, a medical
researcher, about the introduction of buprenor-
phine, a process in which he was involved.
Bore recalled:
When you introduced methadone, you kind of
became tied to it. The way we had to argue for
buprenorphine was different. We had to prove
why it was better than methadone. Because, you
know, they [the politicians] wondered why we
needed yet another substance when we finally had
convinced them that methadone was great, kind
of. Therefore, overdose and diversion were main
topics here.
Asked if there were higher numbers of over-
doses and diversions of medication than before
OST was introduced, he replied, “Yes, we have
more diversion now, because of the wider avail-
ability of the medicines, but the way we are
talking about it has changed”.
In line with other researchers, clinicians, and
health bureaucrats that I interviewed, both
Monstad and Bore emphasised the strong ties
between the government and the clinic in terms
of how pharmaceutical treatment had devel-
oped in recent years. Moreover, as I read Bore,
governmental approval regarding incorporation
of new medication into treatment required a
change in the narrative. Before this attempt,
evaluations of methadone treatment had sug-
gested that the political acceptance of OST was
likely to continue. Clinicians, researchers, and
pharmaceutical companies were compelled to
conduct marketing along new lines.
When studied in isolated and decontextua-
lised conditions (Bartoszko, 2018b), buprenor-
phine is less likely to depress the respiratory
system and less likely to cause overdose, unlike
full agonists such as methadone and morphine.
The drug’s pharmacodynamic qualities, com-
bined with persuasive marketing, have led
many authorities, including Norwegian offi-
cials, to argue that buprenorphine is a safer drug
with respect to risk of overdose and diversion
(Helsedirektoratet, 2010). Thus, together with
the suggested associated reduction in social
risks, the pharmaceutical companies, supported
by the Norwegian clinical community with
their small-scale self-initiated projects, suc-
ceeded in their efforts, and buprenorphine
mono-preparation was accepted as an alterna-
tive in 2002 (Skretting & Dammen, 2004).
Yet treatment effectiveness combined with it
being a viable alternative to existing therapy
was not enough to ensure buprenorphine’s
acceptance. As in other countries following this
pharmaceutical trajectory, the drug had to be
narrated and constructed in relation to existing
methadone treatment (Harris, 2015; Ling et al.,
2010; Netherland, 2011). This time, the main
focus was not primarily on how the drug would
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help individual patients to overcome addiction,
but on its capacity to solve problems associated
with illegal activities (diversion), including
methadone-related deaths, while protecting
public health in general.
Ling et al. (2010) emphasised another factor
that influenced the adoption of innovative med-
ications arising from societal attitudes:
Methadone is not condoned in many circles
because its full agonist properties are seen as too
similar to the effects of the very drug that is being
counteracted—rather than an effective treatment
for the disease state. What is needed in most cases
is a compromise, whereby the treatment for
addiction is effective but not negatively perceived
by society. In that regard, buprenorphine is a
balanced medication, with agonist and antagonist
characteristics that yield minimal reinforcing
effects and negligible noxious side effects. It
meets the needs of both patients and society,
striking a successful therapeutic balance. (Ling
et al., 2010, p. 54)
The strategic over-communication of metha-
done’s high-inducing properties made bupre-
norphine a “light” or, in other words, a more
“public-friendly” version of methadone. In their
history of buprenorphine as an addiction ther-
apeutic in the United States, social scientists
Nancy D. Campbell and Anne M. Lovell
(2012) wrote, “Aimed as both a social and a
pharmacological ‘fix,’ buprenorphine must
work at both levels if it is to work at all—that
is, if buprenorphine is to shed the stigma of
methadone symbolically” (p. 136). Following
that narrative comparison, methadone received
increasingly negative political and public atten-
tion in the following years. Methadone became
marginalised as buprenorphine soared ahead of
other substitution medicines, not only in
quickly increasing prescription rates, but also
in the narrative among clinicians as “the best
medication in the world” (Bartoszko, 2018a).
Within a few years, however, buprenorphine
clearly did not turn out to be the “magic bullet”,
as diversion and overdoses continued. Also,
producer Reckitt Benckiser’s patent for Sub-
utex® was set to expire (Campbell & Lovell,
2012; Sontag, 2013). Responding to the needs
and desires of the market (politicians managing
the treatment in this case), the company inten-
sified its marketing of Suboxone®. This product
combined buprenorphine with naloxone, bring-
ing it under the “technology of suspicion”
(Meyers, 2013, p. 76), which governing bodies
and decision-makers desired and welcomed.
Adding naloxone (an antagonist used as an anti-
dote during opioid overdose to reverse the
opioid effect) was supposed to discourage both
misuse through injection and diversion of the
drug to the illicit market. According to the pro-
ducer, naloxone is inactive when absorbed sub-
lingually, but provokes sudden withdrawals
when injected. However, according to OST
guidelines, “[t]here is no good clinical docu-
mentation confirming the expected effect or
side effects of naloxone if Suboxone® is
injected. Suboxone® received marketing
authorization despite the paucity of studies on
this issue” (Helsedirektoratet, 2010, p. 51).
Suboxone® was registered for use in OST in
2007.
Campbell (2011) noted, “[e]ach technologi-
cal fix in the medicalization of addiction creates
new subjects and new modes of existence” (p.
124). As I explore how Norwegian patients
reacted to this pharmacological innovation and
how the clinicians interpreted those reactions, I
argue that it also creates new modes of resis-
tance. First, however, what kind of buprenor-
phine got into the clinic?
“Buprenorphine is
buprenorphine”
Siv, a 49-year-old OST patient, had been in
treatment with morphine for three years when
OST doctors decided to discontinue her treat-
ment, despite acknowledging that it had been
successful. Siv’s treatment team referred to the
national guidelines and offered her a transfer to
buprenorphine. Rejecting it, she would be
excluded from the programme. Having had a
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negative experience with illicit Subutex® (such
as nausea, anxiety, and persistent cravings), Siv
did not want to change treatment modality.
After a few rounds of meetings and correspon-
dence with OST doctors and consultants with-
out achieving agreement, she filed a complaint
with the County Medical Officer. Having
received a written response to her letter, she
asked me to visit her the following day to help
her scan the document in order to forward it to
the Health and Social Services Ombudsman.
Catching an early morning train, I waited for
her at the park next to the station. She had
received a refusal, and she was furious, saying:
“You have to read this” and “They are out of
their minds! Where are my patients’ rights?”
Letting her dog off the leash, she lit a cigarette
and started reading. The wording was almost
identical to the last letter, which had listed Siv’s
options. She read almost mechanically, giving
the impression that she had already read it a few
times without really paying attention to its con-
tent. She was familiar with the words. Suddenly
she stopped, “What?! Suboxone®?! Are they
going to plunge me completely with it?” She
sounded resigned and a bit scared. In the former
letters and during treatment meetings,
“buprenorphine” or sometimes Subutex® was
a suggested treatment modality. But her reac-
tion told me that the distinction between two
“buprenorphines” (with and without naloxone)
was much more significant than the social sci-
ence and OST literature acknowledge. Simi-
larly, during the consultations that I attended,
the clinical narrative was that “buprenorphine is
buprenorphine”. During the fieldwork, my
impression had been that many physicians and
OST consultants used the names “Subutex®”,
“Suboxone®” and “buprenorphine” inter-
changeably, and they often did not specify
which buprenorphine product they meant.
When I asked Siv if it made any difference, she
almost shouted, “Of course, it does! This is even
fucking worse. I will never survive it! They
must be out of their minds!”
Later, I consulted the OST guidelines for
more details on the two buprenorphine
preparations. Because of Siv’s reaction, I was
particularly interested in the side effects
involved. The guidelines included this:
Blind studies of buprenorphine and the combina-
tion products show few side effects when they are
used properly. A difference between buprenor-
phine with and without naloxone in regard to the
effect or side effect profile is highly unlikely if
the medications are taken properly (sublingually).
Due to the short half-life of naloxone, any phar-
macological effects will also be expected to last a
few hours at most after intake. (Helsedirektoratet,
2010, p. 51)
In its 2015 OST report, the Norwegian Centre
for Addiction Research (SERAF) commented
on buprenorphine dosages:
It is striking that there is a stable pattern that the
combination preparation is dosed lower than the
mono-product. The effect of mono- and combina-
tion preparations should be equivalent and any
potential differences would rather pull towards
the higher doses when using the combination with
antagonist (Suboxone®). A possible explanation
may be the side effects or patient’s anxiety for the
side effects. There may also be less pressure for
high doses because the resale price is low or the
demand low. (Waal et al., 2016, p. 36, my
parenthesis)
These documents did not confirm Siv’s opinion
regarding the dramatic difference between the
two buprenorphine products. On the contrary,
official sources seemed to emphasise the prod-
ucts’ similar effectiveness and side effects. I
visited clinician Jan Erik Winger, one of the
authors of the national OST guidelines, to dis-
cuss the issue. His response was almost a quo-
tation of the guidelines. Interestingly, he
applied the same reasoning to other medica-
tions and their forms, which the patients often
experienced as having different effects on them.
Following are excerpts of our conversation:
Jan Erik Winger: There is no medical
difference [between
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methadone in tablets
and liquid]. There are
some [patients] who say
that the liquid has a
much worse effect com-
pared to the tablets, but
it is exactly the same
thing . . .Therefore, it
is . . . they [patients]
have lots of ideas and
myths.
Researcher: For example?
Jan Erik Winger: That they cannot toler-
ate the liquid, yet they
tolerate tablets.
Researcher: OK, what you are say-
ing is that there are
myths. So how do you
evaluate, as a physician
or researcher, when the
patient says that he can-
not tolerate something,
when he says, “I cannot
tolerate methadone”, or
“I cannot tolerate Sub-
oxone®” or “I feel bad
after morphine?” How
do you assess if this is
all in their minds or
something else?
Jan Erik Winger: Well, one must consider
this in relation to the
biological knowledge
of how things work in
the body. This means
that both known and
unknown side effects
and the difficulties that
could arise within the
body must be taken into
consideration. If it [the
patient’s report] is com-
pletely unreasonable in
relation to all available
medical knowledge,
then you have to say,
“Well, it does not make
sense”. An example
would be methadone
tablets versus liquid.
Both are, in principle,
the same drug. They
work just about the
same without much dif-
ference. This means that
if people cannot tolerate
liquid, they cannot tol-
erate tablets either.
Researcher: You are now speaking
of the effect, not the
form of intake, right?
Jan Erik Winger: Yes, when it comes to
effect, really, it makes
no difference.
According to Winger, clinical studies have
not shown any difference between the two types
of methadone. To explain the reported differ-
ence, he referred to patients’ wish to divert pills
and collective myths and imaginaries. Much
like other OST clinicians, Winger had the same
explanation regarding Subutex® and Sub-
oxone®. However, patients’ experiences with
these medicines challenge the homogenising
narratives and pharmacotopic imaginary of
buprenorphine. Particularly, Siv and many
other patients emphasised the significant differ-
ence between Subutex® and Suboxone®. This
situation illustrates the perpetual debate based
on variances between patient experiences of
symptoms associated with medications and
what physicians can acknowledge or prove
about them. Such debates produce long-
standing dilemmas about biological authenti-
city and who gets to authorise the treatment
experience.
As ethnographic works on buprenorphine
(e.g., Harris, 2015; Meyers, 2013) also tend to
under-communicate the distinction between
buprenorphine products, I posed this problem
to some anthropologists working on the subject.
One of them, Shana Harris, the author of the
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article, “To be free and normal” (Harris, 2015),
responded in our email correspondence:
When I was doing my research, “buprenorphine”
was used synonymously with “Suboxone”. Also,
not much of a distinction was made in interviews
and observations between Suboxone and Subu-
tex. The only time the difference between the
formulations was mentioned was when I was told
that Subutex was only really used during the first
few days of treatment while Suboxone is pre-
scribed for maintenance. (Harris, personal com-
munication, 2016)
Yet, as I have shown, patients in Norway find
this distinction significant, which they made
very explicit. The story of this epistemological
and experiential distinction attracts both
descriptive and analytical attention. It is a testa-
ment to the significance of the local pharma-
ceutical atmospheres and the socio-history of
pharmaceuticals for their effects, understood
as both bodily experiences and socio-political
conditions.
Compulsory transfers
Leah, a 47-year-old OST patient, who had now
been in treatment with Subutex® for four years,
told me about her first meeting with OST. After
her OST consultation, she was prescribed Sub-
oxone® instead of Subutex®, which she pre-
ferred based on her illegal experiences. She
exclaimed recalling the accompanying emo-
tions, “I was scared to death. Imagine! Sub-
oxone®! Antidote!” This mirrors the most
common emotions associated with Suboxone®:
fear and anxiety. The medication, including an
antidote (naloxone) that most heroin users asso-
ciate with the unpleasant withdrawal state
induced by emergency personnel after an over-
dose, elicited negative reactions from many
patients. In general, Suboxone® was considered
bad by the patients I met.
Comparatively, these local narratives are
interesting in light of the Suboxone® stories
described in the literature (Harris, 2015; Lovell,
2006; Meyers, 2013), and a significant factor
could be the patients’ awareness of the drug’s
components. However, I argue that the atmo-
sphere and the contexts that were responsible
for familiarising patients with the product
served to shape its reception and the accompa-
nying resistance.
First, buprenorphine was introduced in Nor-
way as a treatment drug in quick succession to
methadone. The “long shadow” of methadone
apparent in the United States was absent in Nor-
way. Hence, patients did not have the same
long, complicated history with methadone as
their counterparts in the United States, where
local history had generated many negative
experiences of both patients and providers.
Therefore, I argue, when buprenorphine was
introduced in the United States in 2002, the
medication’s “social” contexts and effects in
particular were often compared with those of
methadone and considered more “favourable”
(Harris, 2015) as a result.
Second, the material connection to the
clinic, which Meyers (2014) called “a spatial
locus of therapeutic promise” (p. 188), differs
across the globe. In the United States, metha-
done was distributed in stigmatised and racia-
lised clinics, while buprenorphine was
marketed as “GP friendly”, a doctor’s-office-
based treatment (Bourgois, 2000; Hansen &
Roberts, 2012; Harris, 2015; Netherland,
2011). In Norway, however, methadone treat-
ment, despite patients’ criticism, was often dis-
tributed through pharmacies and never acquired
this type of negative connotation. Thus, bupre-
norphine was introduced and presented as an
alternative to methadone in a similar institu-
tional setting. The symbolism of the place
remained unchanged. Since buprenorphine was
presented as an alternative – at least in theory –
its pharmacological qualities attracted more
attention. Most significant, however, are the
events of 2007.
When the Ministry of Health decided to
replace Subutex® with Suboxone®, all new
patients received Suboxone®, and those receiv-
ing Subutex® or methadone were gradually
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transferred to Suboxone®. A few weeks later,
reports of extensive illicit sales of Subutex® in
the Bergen area of western Norway suggested
that the drug had become more attractive to
drug users than heroin. Expressing concern
over this development, OST centres in Bergen
and Trondheim decided to hasten the Ministry’s
plan and ordered all patients to be put on Sub-
oxone® over the summer. Accordingly, many
patients were subjected to compulsory transi-
tion to Suboxone®, often at the expense of their
existent stable treatment. Approximately 25%
of the patients in Bergen complained of side
effects, including anxiety, nausea, and a variety
of withdrawal symptoms. The Norwegian
Board of Health Supervision received many
medication transfer-related complaints at the
time, and media reports on this politico-
pharmaceutical transition in treatment modality
generated strong protests from users and patient
organisations (Morland, 2007a, 2007b; Sanden,
2007; Sosial- og helsedirektoratet, 2008).
The same “collective transfer” was
attempted in 2010. The Fonna Hospital Trust
(Helse Fonna) in western Norway informed the
Norwegian Board of Health Supervision (inter-
nal documentation):
The OST guidelines refer to a double blinded
study which concludes that there is no difference
between the effects and side effects of Subutex
and Suboxone. We have considered this, as we
cannot allow the subjective differences experi-
enced to influence the choice of medication. The
only professional criterion for Subutex’s eligibil-
ity is pregnancy or objectively proven allergic
reaction to an additive in Suboxone. Therefore,
OST Helse Fonna decided to start a process, the
goal of which was to convert Subutex users to
Suboxone during the spring of 2011. We assume
that this will provoke many complaints to the
Norwegian Board of Health Supervision in Hor-
daland regarding the choice of medication. There-
fore, we are sending this information in advance.
We will not be able to give enough specific rea-
sons for conversion for a single patient beyond
the general information that is given here.
The Board did not accept the organisation’s
decision, and responded by referring to the
Patients’ Rights Act, the OST guidelines, the
Specialist Health Service Act, and the Health
Personnel Act, concluding that a switch of OST
treatment medications must be based on an
individual, thorough assessment of the patient.
Despite the Board’s response, a few of my
interlocutors treated at Fonna Hospital Trust
were subjected to forced transfers. Two moved
to other regions (OST centres) in order to
receive Subutex®/methadone because of the
unwanted effects they experienced with
Suboxone®.
Anne and anxieties
The story of Anne, who was among those
forced to switch medications, highlights the
reciprocal shaping of lived experiences and the
institutional forces surrounding pharmaceutical
use. While illustrating the power of compulsory
transfer, Anne’s story emphasises the intercon-
nectedness of the setting for consumption, the
bodily experience, and perception of consumed
substances (cf. Zinberg, 1984).
Forty-five-year-old Anne had been in suc-
cessful treatment for 12 years, which she and
her OST consultants confirmed. In 2007, she
was treated with Subutex®, and consequently
did not take illicit drugs and was able to main-
tain a job and a meaningful family life with her
children and friends. A home nurse delivered
medication to Anne once a week. One day,
when the nurse came with Suboxone®, Anne
could not understand why the OST had changed
her medication since she had functioned so well
with Subutex®. According to OST and health
authorities, both medications worked the same
way, and the change was safe. “Nevertheless”,
says Anne, “why should I try? I had a good life
finally, stable dosage, no illicit drug use and no
disturbing side effects. Why should I risk this?”
Despite her resistance, she was forced to take
Suboxone®, or go without medication, which,
as a mother of two, she could not afford to risk.
She became very sick after the first pill and
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threw up the medication, which resulted in
withdrawal symptoms. Consequently, she took
more of the medication to get rid of the symp-
toms and became sick every time. During the
entire process she developed serious anxiety,
which remained constant over the following
years when OST doctors tried another three
times to transfer her to Suboxone®. She said,
“Imagine, you are afraid all the time that they
will try to transfer you again. But I got so sick.
And the anxieties. It’s OST’s fault”. When I
asked, “So, you don’t think it was Suboxone®
that had provoked the anxiety?” Anne
responded, “That too. But it was OST’s fault,
all this uncertainty and force and . . .You know,
so many people got sick after that” [the forced
transfer]. The question arises: Was Anne
experiencing side effects from the medication
or from the treatment? Is it possible to separate
the two?
Placebos, nocebos, and
compulsion
Like other patients in her situation, Anne was
told that the medication’s side effects were
“only in her head”, because no evidence indi-
cated such strong differences in patients’ reac-
tions to a buprenorphine with or without
naloxone. Nor was there any evidence indicat-
ing that these products increased anxiety, which
was a common narrative among patients inside
and outside the clinic. Today, the discussions
on the relation between buprenorphine and per-
ceived anxieties has become more nuanced,
even though it is dominated by references to
pharmacological characteristics of the sub-
stance. Physicians either refused to accept
patients’ reports about buprenorphine inducing
or provoking anxieties, or they explained the
experienced anxieties as lacking attenuation,
which patients may receive while using metha-
done, morphine or heroin. For instance, Jan
Erik Skjøla˚s, the psychiatric nurse and head of
the Health and Overdose Team (Helse- og over-
doseteamet) in Trondheim, suggested in the
presentation, “Clinical experiences with use of
Suboxone”, presented at a 2016 national meet-
ing for OST leaders:
Patients wake up. They become clearer in their
heads and they see the challenges in life as they
are without any form of attenuation. As a result,
what they have been through reappears as trauma.
They no longer experience any “veil” that attenu-
ates mental symptoms.
In 2007, however, the debate was much more
polarised and patients’ experiences were simply
dismissed. In one article regarding forced trans-
fers, Steinar Madsen, medical director in the
Norwegian Medicines Agency (Legemiddel-
verket), confirmed that the agency had received
several reports about people becoming ill from
the new medication. He commented:
There are reports of side effects, but only from
Bergen. Non-specific symptoms such as malaise
and nausea are reported. We do not think this has
anything to do with the drug itself [ . . . ] There are
psychological mechanisms [ . . . ] in particular,
because this phenomenon occurs only in Bergen.
(Skotland, 2007)
In the same article, the doctor and senior advi-
sor from the Directorate of Health, Gabrielle
Welle-Strand, said: “It is obvious that some
patients experience discomfort from this drug.
Some reactions may, surely, be attributed to
concerns regarding a new drug and not side
effects of [naloxone]”.
Cultural and social contexts of consumption
shape how patients taking pharmaceuticals per-
ceive and report adverse effects of treatment,
and therefore, when analysing the efficacy of
pharmaceuticals, attention to lived experiences
is particularly important. Nevertheless, as men-
tioned earlier, we must not ignore the biological
body’s contributions to lived experiences. We
need to approach pharmaceutical efficacy as a
complex interconnection of the biological,
sociocultural, and structural factors condition-
ing individuals’ responses to drugs consumed
and their experiences and evaluations of them.
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During the forced transfers, knowledge
regarding Suboxone’s® side effects was sparse.
Some differences in pharmacological effects
cannot be completely rejected; an estimated
10% of naloxone used in Suboxone® is trans-
ferred to the patient’s blood (Sosial- og helse-
direktoratet, 2008). As research documents and
my field experience indicate, individuals may
respond quite differently to the active sub-
stances in a medication, which may apply to the
naloxone component of Suboxone® as well and
could explain some of the troubles patients
reported. However, the magnitude of the prob-
lem did make the prescribing physicians scep-
tical and suspicious towards the patients’
experiences and motives. Clinicians often cited
collective myths (as in the quotation from Jan
Erik Winger) and nocebos to explain the anxi-
eties patients described during consultations,
especially when patients and clinicians did not
agree on treatment modalities.
When I asked a general practitioner, Jørgen
Egeland, about the patients’ strong aversion to
Suboxone®, he confidently said:
It is a nocebo effect, that’s what it is. We have
adequate proof of this from Bergen [ . . . ] we
never witnessed so many side effects of Sub-
oxone® as in Bergen at that point in time and they
were all real side effects. The users got sick . . . So
even if it was a nocebo . . . but nocebo is damn
real. And it is clear that when it has spread . . .
when you have been so foolish with the introduc-
tion of Suboxone®, you are left with lots of
nocebo effects with which it is very hard to make
any kind of progress.
In clinical language, the placebo effect is usu-
ally defined as a physiological positive effect
caused by an inert substance, the placebo. A
placebo response is one that cannot be attrib-
uted to an investigational intervention and is
related to the patient’s perceptions and expec-
tations. If the substance is viewed as helpful, it
can heal, but if it is viewed as harmful, it can
cause negative effects, known as the nocebo
effect. The nocebo response describes a
negative symptom induced by the patient’s own
negative expectations and/or the negative sug-
gestions of clinical staff in the absence of any
treatment or any other source of information. In
pharmacology, the term often relates to the
experience of adverse, nonspecific side effects
that are not the direct result of a specific phar-
macological action of a drug (Barsky, Saintfort,
Rogers, & Borus, 2002).
Egeland’s colleague, Christian Pettersen,
expressed the same view when he said that this
patient group was exceptionally susceptible to
the circulating myths. He noted:
They are very receptive in terms of what I call
nocebo. And also to placebo! In the kind of envi-
ronment they are in, they tend to be influenced by
each another, especially in this culture. This cul-
ture is not always evidence-based, I mean [laugh-
ing], when it comes to pharmacology. A good part
of this is superstition. [ . . . ] and that is the reason
for the Suboxone® nocebo, it is very serious. I
mean, it is very serious. And it will remain very
serious for many years.
As we can see, the placebo and nocebo effects
can be used as explanations that both favour
and disfavour patients, but regardless of how
they are used, they are challenging concepts,
if not problematic. They assume that pharma-
ceuticals are socially inert substances and they
may obfuscate and stigmatise patients’ lived
experiences. These concepts, being a product
of the body–mind dualism are, as Haller
(2014) pointed out, “found almost exclusively
in the biomedical world of reductionist scien-
ce”, which uses these concepts in an attempt to
“build a bridge between the material and the
psychosomatic and behavioural side of healing”
(p. 86). This epistemology places no impor-
tance on the setting for intake of drugs (cf. Zin-
berg, 1984), and does not take into account the
fact that biology is both local and social, or
what Lock and Kaufert (2001) termed “local
biologies”. Anthropologists who study nocebos
and placebos have documented that the “same”
biological and pharmacological processes in
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different pharmaceutical atmospheres may
have different effects (Adler, 2011; Hahn &
Kleinman, 1983; Moerman, 1983, 2002). By
extension, the pharmacological processes may
differ across places and contexts.
Radley (1996) claimed that using the notion
of “placebo effect” to describe effects and reac-
tions to any therapy does not do justice to the
power of social meanings and biographical
events. He noted that referring to phenomena
as placebo effects “suggests, unwisely, a contrast
between the material and the existential spheres,
as if what happens ‘psychologically’ might be
judged separately from (and either better or
worse than) what is done ‘physically’ to the
patient” (1996, p. 134). In Radley’s (1996) anal-
ysis of patients who underwent coronary bypass
surgery, he discussed the operation as
a drama, a realm of significant meaning, in its
evocation of powers that are irreducible to the
cuttings and sewings involved [ . . . It is] a
moment, both in the sense of an instant in time
and as a point about which other events turn, a
kind of liminoid period (Turner, 1982). It is a
critical period, which at once disrupts the per-
son’s life, and yet is presented (by doctors) as the
only route to a healthier existence. It is also a
psychological and social turning point in the life
of the patient [ . . . ] in that it ties together body,
self and personal world to form a parameter about
which biographical reconstruction must take
place. (Radley, 1996, p. 134)
Following this perspective, for the patients sub-
jected to compulsory transfer of medication, the
transfer itself became such a significant and
dramatic event that it influenced not only the
way the new medication was perceived, but
also how it was received.
Suboxone® as metonymy
The involuntary change of treatment modal-
ities, seen as a specific treatment technology,
became significant in the history of the Norwe-
gian OST and altered the pharmaceutical
atmosphere surrounding Suboxone®. According
to Geertz (1995), history is created in the pres-
ent, and is a myth that “does not describe what
happened, but what happens” (p. 3). This more
or less intentional mobilisation and actualisation
of the past helps people orient themselves in
everyday life (Connerton, 1989). The images
of the past create a moral and cognitive frame-
work that manages our expectations of the pres-
ent. Particularly, although not exclusively,
during the process of social change, personal
crises and uncertainties, people switch between
positive and negative judgements of the past;
from a repertoire of memories, they select or
reject those recollections that help them manage
everyday life and legitimise their actions.
From that perspective, I found it necessary to
investigate the “memories of Suboxone®”, as
patients I met were actively engaged in recalling
them during their quest to create meaning in their
current pharmaceutical landscape. An investiga-
tion of this history was crucial to my understand-
ing of the observed continuing resistance
towards Suboxone®. This insight invites an
approach to pharmaceuticals not only as material
entities, but also as metonyms for a disease, a
doctor, or in this case, a treatment policy based
on coercion and compulsion. Van der Geest and
Whyte (1989) wrote, “The medicine stands for a
less tangible experience of which it was a part, as
the seashell serves as a memento for the beach
one has known as a child” (p. 359).
By using their power to compulsorily change
treatment modalities, the clinicians sent signif-
icant signals to the patients. Through Sub-
oxone®, they communicated their power,
authority, and diagnostic supremacy as well as
their attitudes, values, and priorities, which
patients interpreted as a homogenisation of
individuals and collective suspicion of patients’
motives. Arild Knutsen, a leader of the Norwe-
gian Association for Human Drug Policies
(FHN), expressed his reaction to the events in
Bergen in 2007:
Notification of the collective transfer created
great unrest. Many patients feared that their body
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would not manage the transition. The fact that
everybody had to switch their medication was
also perceived as a collective punishment. A
woman reported that she felt treated like a drug
addict again, many years after she could tie her
identity to such a category.
Therefore, the forced transfer as a “mark on
one’s biography” (Radley, 1996, p. 132) had
implications for patients’ evaluation of the ther-
apy, the healthcare provided, and of themselves.
To patients, the transfer represented disrespect of
their treatment, their experiences, and their indi-
viduality. It also made them question the sincer-
ity of clinical recommendations and the validity
of the laws expressed in the Patients’ Rights Act,
which guarantees the right to individualised
treatment, informed consent, and patient invol-
vement. The forced transfers shaped local social
meanings attached to this particular medication,
which significantly differed from those attached
to methadone and Subutex®.
Against this backdrop, we can better under-
stand that patients harbour negative feelings and
reactions against Suboxone®, even if the practice
has changed with guidelines emphasising
patients’ right to choose a modality. Anne, Siv,
Leah, and others associated Suboxone® with
anxieties and lost autonomy. The medication
bore symbolic and clinico-political meanings,
which had real-life consequences for patients
and for professionals who struggled with
patients’ resistance (Bartoszko, 2018a). I often
heard patients say, “Remember what they did to
us in Bergen”. The embodied social memory of
those events is more powerful than any current
claims from the medical community and consti-
tutes a major part of this medication’s effect.
Through this particularly disempowering
politico-pharmaceutical intervention, the new
capacities of Suboxone® were constructed.
Polluting pharmaceutical
atmospheres
Through the rhetoric and argumentations cited
above, we can observe how patients and
medical experts alike ascribed new meanings
to the materiality of Suboxone® and actively
contributed to a different understanding of
pharmaceutical work, thus producing different
types of buprenorphine. Both patients and pro-
fessionals found various implications for the
side effects of Suboxone®. They sought to
understand these in different, often inconsistent
ways. The experienced and ascribed side effects
harboured potent ideas that symbolise the role
substitution medication played for the OST
patients. The medical community on the other
hand, operated with homogenising narratives of
buprenorphine(s) and the effects, focusing pre-
dominantly on pharmacological properties. By
placing Suboxone® in the network of its sym-
bolic meanings, I have illustrated that the sig-
nificant focus on the side effects of Suboxone®
in Norway was a result of individual idiosyn-
cratic experiences, social history of treatment
and medication, the internalised notion of
choice possibilities, and user involvement
expressed by the law and medical guidelines.
In 2011, Campbell asked:
What discourses, policies and practices will the
globalization of buprenorphine—either its “pure”
form, Subutex, or mixed with naloxone, Subox-
one—yield in terms of new subject formations,
and how will they be positioned in relation to
“addiction”? What new addict subject formations
will be produced through interaction with inter-
national harm reduction movements, human
rights discourse or the pharmaceutical industry?
(Campbell, 2011, p. 134)
Outlining the local receptions and perceptions
of buprenorphine(s), I have posited that in Nor-
way this pharmaceutical innovation had not
only clinical, but also social and political con-
sequences shaping new pharmaceutical subjec-
tivities. Contrary to Harris’ (2015) findings,
patients’ experiences with this treatment mod-
ality were reflected and affected by the dis-
course of compulsion and disenfranchisement
instead of freedom and normalcy. In Norway,
the way buprenorphine-naloxone was
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introduced altered the therapeutic atmosphere
of OST, leaving deep traces in the patients’
bodies. It fostered a sense of disrespect, failure,
and mistrust in patients. The involuntary
change of treatment modalities became signifi-
cant in the history of the Norwegian OST,
which profoundly changed buprenorphine’s
future and its role in the treatment landscape.
It also weakened and at the same time, strength-
ened patients’ self-perceptions and self-
positioning as equal citizens having the right
to individual treatment.
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Notes
1. Despite an initial acknowledgement of the differ-
ence between buprenorphine with and without
naloxone, Harris is not explicit about the distinc-
tion in her analysis, writing about
“buprenorphine” in general. In this article, unless
otherwise specified, “buprenorphine” encom-
passes both buprenorphine products, with and
without naloxone. For the sake of empirical and
analytic clarity, I use specific brand names (Sub-
utex® and Suboxone®) when appropriate.
2. Subsequently in this article, I do not include the
names of generic equivalents of the drugs or var-
ious producers for simplification purposes and
also because my interlocutors rarely referred to
them. Even patients using cheaper generic ver-
sions (such as Buprenorphine Orifarm or Bupre-
norphine Sandoz) often referred to it as Subutex®;
during general discussions as well as in OST
annual reports, this brand name was used most
frequently. The same was true for Suboxone®,
which was the only buprenorphine-naloxone
product in Norway at the time of my fieldwork.
3. This recommendation indicates that the Directo-
rate of Health regard the events of 2007 (analysed
in this article) and the subsequent protests as
significant.
4. All names have been changed to ensure
confidentiality.
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